The potential anti-amyloidogenic candidate, SPA1413, for Alzheimer's disease.
Seong Soo A AnKyu Hwan ShimShinwoo KangYoung Kyo KimLalita SubediHyewon ChoSeong-Min HongMario A TanRaok JeonKeun-A ChangSun Yeou KimPublished in: British journal of pharmacology (2021)
Our results strongly support the repurposing of SPA1413, which has already received fast-track status from the US Food and Drug Administration (FDA) for cancer treatment, for the treatment of Alzheimer's disease due to its potent anti-amyloidogenic and anti-neuroinflammatory actions.